Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.

Antiviral therapy - 1 Jan 1999

Soriano V

Abstract excerpt

The ERASE Spanish Study Group was founded in 1997 with the primary objective of monitoring both the prevalence and impact of the development of resistance to antiretroviral drugs in HIV-infected sentinel populations. Two major studies, one in 1997 and another in 1998, have been conducted so far. Global data and results derived from substudies are summarized in this presentation.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cross-Sectional Studies
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to HIV Protease

Share to HIV Reverse Transcriptase

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 16021872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.PMID 16021872Read ↗

Changes in the rate of genotypic resistance to antiretroviral drugs in Spain.Semantic proximity Read ↗

[Epidemiology of drug-resistant HIV-1 transmission in naïve patients in Spain].Semantic proximity Read ↗

Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.Semantic proximity Read ↗

Prevalence of genotypic resistance in untreated HIV patients in Spain.Semantic proximity Read ↗

Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade.Semantic proximity Read ↗

Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class.Semantic proximity Read ↗

Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid.Semantic proximity Read ↗

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.Semantic proximity Read ↗

Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors.Semantic proximity Read ↗

Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.Semantic proximity Read ↗

Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.